proteas
cell
entri
block
experiment
establish
drug
viru
replic
assembl
inhibit
antivir
drug
target
viral
rnadepend
rna
polymeras
rdrp
main
proteas
mpro
abstract
outbreak
pandem
coronaviru
challeng
global
health
futur
vaccin
viru
avail
near
futur
herein
tri
offer
pharmacolog
strategi
combat
viru
exist
number
candid
drug
may
inhibit
infect
replic
drug
compris
inhibitor
serin
proteas
inhibitor
angiotensinconvert
enzym
blockad
host
cell
receptor
protein
inhibit
requir
protein
prime
may
prevent
cell
entri
chloroquin
hydroxychloroquin
offlabel
antivir
drug
nucleotid
analogu
remdesivir
hiv
proteas
inhibitor
lopinavir
ritonavir
broadspectrum
antivir
drug
arbidol
favipiravir
well
antivir
phytochem
avail
date
may
prevent
spread
morbid
mortal
pandem
exopeptidas
express
epitheli
cell
respiratori
tract
may
constitut
pharmacolog
target
limit
cell
entri
establish
antimalari
drug
chloroquin
hydroxychloroquin
shown
inhibit
termin
phosphoryl
elev
ph
endosom
respect
chloroquin
hydroxychloroquin
constitut
candid
drug
sarscov
infect
diseas
investig
therapeut
efficaci
intern
clinic
trial
patient
e
solidar
trial
glycosyl
protein
sarscov
highli
immunogen
host
immun
system
murin
polyclon
antibodi
sarscov
protein
potent
inhibit
smediat
cell
entri
indic
crossneutr
antibodi
target
conserv
epitop
elicit
upon
vaccin
similar
earlier
sar
mer
beta
coronavirus
primarili
infect
alveolar
epitheli
cell
lung
lead
sever
bilater
peripher
pneumonia
ground
glass
opac
ct
imag
diseas
mortal
rate
also
contribut
multipl
organ
failur
affect
heart
liver
kidney
central
nervou
system
gastrointestin
tract
epidemiolog
thu
far
suggest
contagi
sarscov
merscov
multipl
mechan
identifi
infect
replic
process
offer
target
pharmacolog
intervent
infect
pneumocyt
macrophag
pulmonari
mast
cell
requir
viral
protein
invas
process
involv
attach
protein
receptor
facilit
host
cell
deriv
serin
proteas
agent
inhibit
camostat
mesil
may
use
block
viral
host
cell
entri
host
cell
entri
viral
singlestrand
posit
rna
releas
replic
viru
rna
translat
viru
polyprotein
final
cleav
matur
effector
protein
viru
proteas
protein
interact
host
cell
cytoplasm
membran
initi
viral
infect
strategi
capabl
disrupt
protein
interact
could
signific
therapeut
valu
bind
affin
protein
higher
protein
sarscov
may
contribut
higher
contagi
compar
sarscov
although
sarscov
genom
sequenc
similar
share
highli
conserv
receptor
bind
domain
protein
also
potenti
target
highli
conserv
protein
associ
sarscov
includ
rdrp
also
term
mpro
share
similar
two
virus
despit
genom
sequenc
share
rdrp
rnadepend
rna
polymeras
requir
replic
viral
genom
within
host
cell
plpro
viral
proteas
break
viral
polyprotein
function
unit
within
host
cell
final
assembl
new
virus
sequenc
two
virus
similar
plpro
sequenc
ident
activ
site
show
high
degre
conserv
drug
recent
shown
target
merscov
mice
inhibit
ebola
viru
rdrp
proteas
human
remdesivir
ritonavirlopinavir
also
constitut
candid
drug
investig
therapeut
efficaci
patient
intern
clinic
trial
solidar
trial
discoveri
trial
final
certain
phytochem
natur
product
high
antivir
activ
consid
treatment
infect
diseas
result
previou
studi
reveal
divers
virus
includ
ebola
viru
sarscoronaviru
sarscov
merscoronaviru
merscov
influenza
viru
employ
host
cell
proteas
activ
envelop
glycoprotein
cleavag
activ
spike
protein
protein
sarscov
requir
membran
fusion
host
cell
entri
mediat
transmembran
proteaseserin
subfamili
member
airway
alveolar
cell
serin
proteas
cowork
recent
demonstr
also
employ
protein
prime
proteindriven
cell
entri
use
camostat
mesil
clinic
proven
commerci
serin
proteas
inhibitor
partial
block
infect
chronic
pancreat
camostat
mesil
manufactur
oral
drug
nichiiko
pharmaceut
co
ltd
ono
pharmaceut
japan
three
time
daili
dose
recommend
mg
mg
clinic
trial
investig
camostat
mesil
dyspepsia
associ
nonalcohol
mild
pancreat
diseas
patient
receiv
mg
camostat
mesil
three
time
daili
week
show
mild
sever
advers
effect
indic
camostat
mesil
welltoler
drug
nafamostat
mesil
buipel
tm
benzoatedimethanesulfon
ca
number
clinic
proven
synthet
serin
proteas
inhibitor
approv
japan
treatment
acut
pancreat
dissemin
intravascular
coagul
anticoagul
extracorpor
circul
screen
approach
drug
approv
fda
nafamostat
mesil
identifi
inhibit
merscov
proteinj
u
r
n
l
p
r
e
p
r
f
mediat
viral
membran
fusion
lung
host
cell
inhibit
proteas
activ
sinc
protein
merscov
share
consider
amino
acid
sequenc
homolog
nafamostat
mesil
may
also
inhibit
cell
entri
cell
cultur
experi
simian
vero
cell
infect
nafamostat
mesil
shown
inhibit
infect
suggest
nafamostat
mesil
abl
prevent
infect
multicent
random
openlabel
phase
trial
patient
sever
acut
pancreat
nafamostat
mesil
administ
intraven
daili
dose
mg
day
without
sever
advers
effect
sarscov
relat
coronavirus
directli
interact
via
protein
angiotensinconvert
enzym
host
cell
exopeptidas
metallocarboxypeptidas
catalys
convers
angiotensin
nonapeptid
angiotensin
convers
angiotensin
ii
angiotensin
initi
proteinmedi
cell
entri
demonstr
recent
also
use
receptor
proteindriven
host
cell
entri
therefor
constitut
molecular
target
inhibit
cell
entri
unfortun
ace
inhibitor
standard
drug
treatment
hypertens
chronic
heart
failur
fail
inhibit
number
drug
compound
shown
inhibit
chloroquin
phosphat
resochin
tm
deriv
hydroxychloroquin
quensyl
tm
plaquenil
tm
hydroquin
tm
dolquin
tm
quinor
tm
use
decad
prophylaxi
treatment
malaria
treatment
chronic
q
fever
variou
autoimmun
diseas
recent
demonstr
potenti
broadspectrum
antivir
drug
chloroquin
phosphat
inhibit
termin
phosphoryl
hydroxychloroquin
elev
ph
endosom
involv
viru
cell
entri
mechan
constitut
relev
antivir
mechan
chloroquin
hydroxychloroquin
vivo
hydroxychloroquin
metabol
chloroquin
chloroquin
phosphat
previous
shown
inhibit
sarscov
infect
spread
vitro
result
recent
studi
reveal
chloroquin
phosphat
effect
hydroxychloroquin
also
inhibit
replic
simian
vero
cell
use
physiologicallybas
pharmacokinet
model
chloroquin
phosphat
hydroxychloroquin
human
lung
fluid
demonstr
concentr
hydroxychloroquin
recommend
treatment
infect
compris
oral
load
dose
mg
twice
daili
day
follow
oral
mainten
dose
mg
twice
daili
j
u
r
n
l
p
r
e
p
r
f
day
result
deduc
vitro
data
obtain
vero
cell
treat
hydroxychloroquin
recent
pilot
trial
conduct
hospit
wuhan
jingzhou
guangzhou
beje
shanghai
chongq
ningbo
china
patient
diseas
demonstr
treatment
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
laboratori
virusneg
convers
shorten
cours
diseas
chloroquin
phosphat
administ
oral
daili
dose
mg
clinic
convalesc
thu
view
result
urgent
clinic
demand
regard
pandemia
chloroquin
phosphat
recommend
treat
associ
pneumonia
larger
popul
recent
openlabel
nonrandom
clinic
trial
conduct
march
franc
patient
treat
daili
mg
hydroxychloroquin
day
demonstr
day
neg
viral
load
neg
nasopharyng
pcr
hydroxychloroquinetr
patient
compar
neg
viral
load
untreat
patient
control
group
random
clinic
trial
conduct
februari
wuhan
china
sixti
two
patient
random
receiv
either
daili
mg
hydroxychloroquin
day
pharmacolog
treatment
improv
absorpt
pneumonia
analyz
chest
ct
day
observ
hydroxychloroquinetr
patient
vs
untreat
patient
result
small
studi
therefor
strongli
suggest
hydroxychloroquin
therapeut
efficaci
thu
consider
number
clinic
trial
investig
therapeut
efficaci
chloroquin
phosphat
hydroxychloroquin
patient
infect
diseas
initi
china
great
britain
spain
thailand
tripl
combin
cepharanthin
antiinflammatori
alkaloid
stephania
cepharantha
whose
protein
share
amino
acid
ident
demonstr
also
use
receptor
viral
cell
entri
two
librari
clinic
approv
drug
screen
abil
inhibit
cytopath
effect
vero
cell
combin
cepharanthin
selamectin
mefloquin
hydrochlorid
identifi
candid
drug
combin
sar
j
u
r
n
l
p
r
e
p
r
f
shortli
identif
angiotensinconvert
enzym
metallocarboxypeptidas
mediat
variou
cardiovascular
renal
function
peptid
inhibitor
enzym
develop
select
constrain
peptid
librari
display
phage
potent
inhibitor
term
amino
acid
sequenc
ac
vero
cell
inhibit
infect
engin
human
capillari
organoid
kidney
organoid
isol
nasopharyng
sampl
patient
confirm
diseas
suggest
block
host
cell
entri
earli
stage
infect
remdesivir
ca
number
novel
smallmolecul
adenin
nucleotid
analogu
antivir
drug
shown
efficaci
ebola
viru
rhesu
monkey
oncedaili
intraven
administr
mg
kg
remdesivir
day
result
profound
suppress
ebola
viru
replic
protect
ebola
virusinfect
anim
lethal
diseas
remdesivir
display
antivir
activ
singl
strand
rna
virus
includ
filovirus
pneumovirus
paramyxovirus
coronavirus
merscov
sarscov
remdesivir
prodrug
metabol
activ
form
adenin
nucleotid
analogu
interfer
activ
viral
rna
polymeras
promot
evas
j
u
r
n
l
p
r
e
p
r
f
proofread
viral
exoribonucleas
lead
inhibit
viral
rna
synthesi
remdesivir
act
earli
infect
decreas
viral
rna
level
dosedepend
manner
parallel
impair
viral
load
vitro
relat
mechan
action
remdesivir
demonstr
vitro
sarscov
ebola
viru
merscov
recent
studi
demonstr
cell
cultur
experi
simian
vero
cell
infect
remdesivir
inhibit
infect
concentr
achiev
vivo
nonhuman
primat
model
shown
remdesivir
effici
inhibit
infect
human
liver
cancer
cell
sensit
infect
usa
franc
lopinavir
highli
potent
inhibitor
human
immunodefici
viru
hiv
proteas
essenti
intracellular
hiv
assembl
develop
circumv
hiv
resist
toward
proteas
inhibitor
ritonavir
caus
mutat
valin
posit
val
activ
site
hiv
proteas
respons
ritonavir
therapi
metabol
lopinavir
strongli
inhibit
ritonavir
concomit
oral
administr
lopinavir
ritonavir
exceed
vitro
antivir
lopinavir
h
rat
dog
monkey
plasma
j
u
r
n
l
p
r
e
p
r
f
coadministr
mg
lopinavir
mg
ritonavir
enhanc
healthi
human
volunt
area
concentr
curv
lopinavir
plasma
observ
dose
lopinavir
alon
mean
concentr
lopinavir
exceed
h
therefor
combin
lopinavir
ritonavir
kaletra
tm
establish
effect
oral
drug
treatment
hivinfect
individu
use
combin
antiretrovir
agent
initi
studi
demonstr
lopinavir
inhibit
cytopath
effect
plaqu
reduct
assay
fetal
rhesu
infect
sarscov
isol
studi
newli
diagnos
sar
patient
infect
sarscov
treat
combin
lopinavir
mg
ritonavir
mg
oral
everi
hour
day
day
sar
patient
treat
lopinavirritonavir
milder
diseas
cours
term
diarrhea
recurr
fever
worsen
chest
radiograph
reduct
viral
load
compar
histor
control
group
nonhuman
primat
model
common
marmoset
infect
merscov
lopinavirritonavirtr
anim
display
improv
clinic
outcom
compar
untreat
anim
improv
weight
loss
lung
imag
patholog
find
lower
mean
viral
load
necropsi
lung
extrapulmonari
tissu
respons
find
ongo
random
control
trial
miracl
trial
initi
determin
therapeut
efficaci
lopinavirritonavir
combin
interferon
patient
infect
merscov
recent
treatment
lopinavirritonavir
associ
differ
standard
care
time
clinic
improv
mortal
day
similar
lopinavirritonavir
group
standardcar
group
moreov
treatment
lopinavirritonavir
treatment
reduc
viral
rna
load
durat
viral
rna
detect
compar
standard
support
care
rna
still
detect
patient
lopinavirritonavir
group
end
trial
day
howev
number
lopinavirritonavir
recipi
seriou
complic
acut
kidney
injuri
secondari
infect
requir
noninvas
invas
mechan
ventil
respiratori
failur
fewer
receiv
lopinavirritonavir
treatment
result
observ
requir
addit
studi
determin
whether
treatment
lopinavirritonavir
given
certain
diseas
stage
reduc
complic
patient
china
hong
kong
republ
korea
europ
discoveri
trial
investig
remdesivir
lopinavirritonavir
lopinavirritonavir
plu
interferon
umifenovir
view
promis
clinic
result
clinic
trial
umifenovir
alon
combin
lopinavirritonavir
chloroquin
phosphat
carrimycin
recent
initi
china
human
receptor
tocilizumab
favipiravir
combin
chloroquin
phosphat
viral
neuramidas
inhibitor
oseltamivir
initi
recent
china
also
term
mpro
constitut
main
proteas
beta
coronavirus
essenti
process
polyprotein
translat
viral
rna
recent
xray
structur
unlig
complex
design
specif
inhibitor
report
two
pyridinecontain
design
display
favor
pharmacokinet
properti
mice
detect
suffici
concentr
lung
tissu
broncheoalveolar
lavag
fluid
within
hour
hour
subcutan
administr
demonstr
lung
tropism
compound
besid
subcutan
administr
inhal
nebul
mice
result
high
longlast
hour
concentr
lung
tissu
without
advers
effect
point
role
pyridinecontain
therapi
recent
studi
employ
combin
structureassist
drug
design
virtual
drug
screen
highthroughput
screen
mechanismbas
inhibitor
mpro
term
identifi
computeraid
drug
design
michael
acceptor
inhibitor
inhibit
mpro
sarscov
merscov
shown
form
coval
bond
irrevers
inhibitor
mpro
highthroughput
screen
approach
identifi
inhibitor
mpro
ebselen
organoselenium
compound
antiinflammatori
antioxid
cytoprotect
properti
identifi
plaquereduct
assay
simian
vero
cell
infect
ebselen
display
antivir
cell
protect
efficaci
valu
respect
ultim
demonstr
antivir
potenti
natur
product
inhibit
variou
step
viral
infect
replic
mani
broadspectrum
antivir
effect
mechan
fulli
character
also
function
immunomodul
suppress
inflammatori
reaction
respons
major
morbid
mortal
infect
phytochem
especi
flavonoid
wide
distribut
food
plant
botan
shown
interfer
inflammasom
signal
respiratori
distress
syndrom
associ
sar
coronavirus
develop
part
due
viral
activ
inflammasom
within
activ
macrophag
lymphocyt
caus
increas
product
inflammatori
cytokin
sever
flavonoid
interfer
activ
inflammasom
may
modul
inflammatori
respons
sar
beta
coronavirus
luteolin
myricetin
apigenin
j
u
r
n
l
p
r
e
p
r
f
quercetin
kaempferol
baicalin
wogonosid
flavonoid
shown
activ
wide
varieti
virus
via
multipl
mechan
avail
nutraceut
supplement
daili
dose
rang
mg
mg
emodin
ca
number
anthraquinon
compound
found
variou
chines
herb
also
produc
mani
speci
fungi
includ
member
genera
aspergillu
pyrenochaeta
pestalotiopsi
emodin
shown
inhibit
interact
sarscov
protein
receptor
dosedepend
manner
suggest
resveratrol
may
also
effect
infect
emerg
novel
beta
coronaviru
wuhan
hubei
provinc
china
decemb
rapidli
led
pandem
involv
infect
person
proven
drug
camostat
mesil
prevent
viru
host
cell
entri
inhibit
chloroquin
phosphat
inhibit
termin
phosphoryl
hydroxychloroquin
metabol
vivo
chloroquin
treatment
ordinari
sever
pneumonia
lower
mortal
rate
diseas
antivir
drug
remdesivir
favipiravir
umifenovir
lopinavirritonavir
plu
interferon
administ
particular
consider
preliminari
result
recent
ongo
clinic
trial
solidar
discoveri
cn
dlm
conceiv
origin
idea
wrote
larg
part
manuscript
us
wrote
section
prepar
tabl
figur
sl
finish
manuscript
none
conflict
interest
sincer
